Table 1.
Baseline characteristics
| Patients (n = 35) | |
|---|---|
| Age | 58 ± 9 years |
| Male | 29 (83%) |
| Hypertension | 11 (26%) |
| Hypercholesterolemia | 7 (17%) |
| Total cholesterol, mmol/L | 4.9±0.8 mmol/L |
| Diabetes | 1 (2%) |
| Smoking | |
| Non | 10 (24%) |
| Active | 18 (43%) |
| Ex | 14 (33%) |
| Family history of premature CAD | 17 (41%) |
| Peripheral arterial disease | 0 |
| Infarct location | |
| LAD | 17 (49%) |
| RCA | 15 (42%) |
| LCX | 2 (6%) |
| LM | 1 (3%) |
| TIMI flow prior to pPCI | |
| 0 | 17 (49%) |
| 1 | 8 (23%) |
| 2 | 5 (14%) |
| 3 | 5 (14%) |
| TIMI flow post-pPCI | |
| 0 | 1 (2%) |
| 1 | 0 |
| 2 | 3 (9%) |
| 3 | 31 (89%) |
| Peak troponin T, ng/mL | 5769 ± 6201 |
| Peak CK-MB, U/I | 247 ± 175 |
| Ejection fraction post-pPCI at discharge, % | 43.8 ± 9.6 |
| Time from symptom-onset to PCI, minutes (IQR) | 165 (120–273) |
| Medication during follow-up | |
| ACE/ARB | 11 (31%) |
| Beta-blockers | 31 (88%) |
| Statins | 35 (100%) |
| Thiazide/loop diuretic | 6 (17%) |
| Acetylsalicylic acid | 35 (100%) |
| ADP antagonist | 35 (100%) |
CAD, coronary artery disease; LAD, left anterior ascending artery; RCA, right coronary artery; LCX, left circumflex artery; LM, left main artery; TIMI, thrombolysis in myocardial infarction; pPCI, post-primary percutaneous intervention; CK-MB, Creatine-kinase MB; IQR, interquartile range; ACE/ARB, angiotensin-converting-enzyme inhibitor/angiotensin receptor II blocker; ADP antagonist, adenosine diphosphate (ADP) receptor inhibitor